Squarepoint
ELDN icon

Squarepoint’s Eledon Pharmaceuticals ELDN Stock Holding History

Squarepoint’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,297
Closed -$94K – 4417
2025
Q3 		$94K Buy
36,297
+19,553
+117% +$57.2K ﹤0.01% 4125
2025
Q2 		$45.4K Sell
16,744
-11,969
-42% -$35.9K ﹤0.01% 4318
2025
Q1 		$97.3K Buy
+28,713
New +$118K ﹤0.01% 4228
2017
Q1 		– Sell
-164
Closed -$26K – 1613
2016
Q4 		$26K Buy
+164
New +$31.4K ﹤0.01% 1722

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Squarepoint's ELDN Position: Q4 2025 in Review

Squarepoint sold out of Eledon Pharmaceuticals (ELDN) in Q4 2025, closing a stake of 36,297 shares — an estimated $94K sold.

Squarepoint first reported a position in ELDN in Q4 2016 and held it in 4 quarters. The position peaked at $97.3K in Q1 2025. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • Squarepoint reported no remaining Eledon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 36,297 Eledon Pharmaceuticals shares in Q4 2025, an estimated $94K.
  • Squarepoint first reported a position in Eledon Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Squarepoint's Eledon Pharmaceuticals position peaked at $97.3K in Q1 2025.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.